Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
featured
COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator

The study is designed to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19.  The investigational medication is called CD24Fc. Participants will be randomly assigned to one of two treatment "arms" for the study and neither the participant, nor the study team will …

  • 3989 views
  • 17 Jun, 2020
  • 4 locations
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

disease or disorder
natalizumab
mitoxantrone
  • 9 views
  • 08 Nov, 2020
Efficacy and Tolerability of Sensoril in Improving Immunity and Thereby Reducing Incidence of Upper Respiratory Tract Infections

to assess the efficacy and safety of a standardized Withania somnifera extract (Sensoril) as an immunomodulator in individuals suffering from recurrent URTIs. The study population will be

  • 0 views
  • 05 Jul, 2021
  • 3 locations
Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma

Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to

  • 0 views
  • 24 May, 2021
  • 1 location
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

responses have been observed in a cohort of heavily pretreated patients with relapsed/refractory MM. The use of a treatment combination with monoclonal antibody associated with immunomodulator (in a four

  • 0 views
  • 22 Jan, 2021
  • 1 location
Pegloticase and Methotrexate Co-administered in Patients With Uncontrolled Gout Who Have Previously Failed Pegloticase Monotherapy

concomitant immunomodulator and stopped pegloticase due to failure to maintain sUA (serum uric acid) response and/or a clinically mild IR (infusion reaction). Approximately 30 participants will be enrolled

  • 0 views
  • 09 Jul, 2021
  • 15 locations
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

microenvironment in regulation of intratumoral immune regulators (i.e. T-regulatory cells) in improving response to Durvalumab To understand the role of AZD5363 as an immunomodulator To evaluate

  • 0 views
  • 22 Jan, 2021
  • 1 location
Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial

Cirrhotic patients are predisposed to bacterial infection. A large proportion of which is spontaneous bacterial peritonitis(SBP), which are mainly caused by enteric bacteria.SBP in a cirrhotic patients is associated with a high mortality rate in the order of 30-80% per year.It has been demonstrated that cirrhotics who have an ascitic …

ascites
spontaneous bacterial peritonitis
norfloxacin
antibiotics
cirrhosis
  • 6 views
  • 07 Nov, 2020
  • 1 location
Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation

Since the introduction of calcineurin-based immunosuppression, patient and graft survival in pediatric liver transplantation (LT) improved significantly. However, in contrast, calcineurin inhibitor (CNI) toxicity leads to significant morbidity and impairs quality of life for recipients. Moreover, CNI cannot prevent long-term allograft inflammation and fibrosis. Mesenchymal stem (stromal) cells (MSC) have …

  • 9 views
  • 22 Jan, 2021
  • 1 location
Synergetic B-cell Immunomodulation in SLE - 2nd Study.

In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.

vasculitis
elisa
pericarditis
azathioprine
belimumab
  • 10 views
  • 07 Mar, 2021
  • 4 locations